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Previously, we reported two cDNAs derived from the Marek's disease virus (MDV) long internal repeat region. A 14-kDa 
polypeptide (p14) encoded by two small open reading frames (ORFs) from at least two distinct cDNAs is expressed in cells 
lytically infected with both oncogenic and attenuated MDV as well as in cells latently infected and transformed by MDV. In 
this study, we demonstrate that p14 is serotype 1 specific and highly phosphorylated. Given the degree of phosphorylation 
and lack of homology to known proteins, we propose the name pp14 for the polypeptide ncoded by ORFla and ORFlb. 
Further analysis reveals that pp14 is predominantly found in cytoplasmic fractions of MDV-infected cells and can be detected 
in the cytoplasm of MDV-infected cells by immunofluorescence with polyclonal antisera prepared against pp14-glutathione 
S-transferase fusion protein. © 1995 Academic Press, Inc. 
Marek's disease virus (MDV) is an oncogenic avian 
herpesvirus which induces lymphoproliferative disease 
and demyelination of peripheral nerves in chickens (4, 
8). MDV-induced disease, Marek's disease, was one of 
the first neoplastic diseases associated with a herpesvi- 
rus. Although MDV has been effectively controlled by 
vaccination with an antigenically related but apathogenic 
herpesvirus of turkeys (HVT), the mechanism of MDV- 
induced tumorigenicity is poorly understood. 
The MDV genome is double-stranded DNA with a 
structure similar to that of human alpha-herpesviruses, 
such as varicella-zoster virus and herpes simplex virus. 
MDV DNA consists of unique long (UL) and unique short 
(Us) regions, each bounded by a set of inverted repeats 
(TRL, IRL, IRs, and TRs) (5, 1 1). The repeat regions of MDV 
have attracted attention by many investigators for several 
reasons; First, genes encoded in herpesvirus repeat re- 
gions are more varied and tend to be virus specific (3). 
Second, abundant transcripts of immediate-early genes 
are detected in these regions (21, 28). Third, and perhaps 
most important, transcripts derived from repeat regions 
may be related to MDV oncogenicity (1, 2). Previous stud- 
ies have revealed that serial in vitro passage of virulent 
MDV in primary chicken embryo fibroblast (CEF) cells 
results in loss of MDV tumorigenicity. This attenuation 
was strongly correlated with amplification of a specific 
132-bp repeat sequence located within the MDVTRL and 
IRE (BamHI-H and -D fragments, respectively) (7, 11, 20, 
29). Bradley et al. (1, 2) reported that a 1.8-kb BamHI-H 
gene family is transcribed rightwardly from the expanded 
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region. Expression of these transcripts in cells infected 
with oncogenic MDV, but not in attenuated MDV, sug- 
gested an association of this gene family with MDV tu- 
morigenicity. This hypothesis was supported by anti- 
sense inhibition of MDV-induced lymphoblastoid cell line 
proliferation, using an oligonucleotide complementary to 
the putative splice donor sequence of the 1.8-kb gene 
family (19). A cDNA library from this BamH I-H gene family 
was developed by Peng et al. (23) with identification of 
four cDNA clones. Two cDNAs (1.69 and 2.2 kb) were 
reported as nonspliced transcripts, while two other 
cDNAs (1.5 and 1.9 kb) were recognized as single- 
spliced transcripts spanning MDV BamHI-H and BamHI- 
12 fragments. Recently, Peng et al. (24) reported that two 
transcripts from this region (1.69 and 1.5 kb) can induce 
prolonged proliferation and reduced serum dependence 
of primary CEF in transfection assays. Peng et al. (24) 
suggested that one function of the BamHI-H gene family 
may be cell-growth control. Additional transcripts that 
initiate or terminate within or near the 132-bp repeat 
region have also been described (7). In addition, a 38- 
kDa phosphoprotein (pp38), expressed in both MDV lyti- 
cally infected cells and transformed lymphoblastoid cell 
lines was localized to the BamHI-H region, left of the 1.8- 
kb gene family, and transcribed in a leftward direction 
(6, 9). 
The meq gene, a basic-leucine zipper gene and partial 
homolog of the fos/jun oncogene family, has been 
mapped to the rightward region of BamHl-12 and is ex- 
pressed in MDV-transformed lymphoblastoid cell lines 
but not in cells lytically infected with MDV strain GA 
(18). Differences between reports on size, number, and 
direction of transcripts derived from MDV repeat regions 
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have made these regions the most controversial and 
apparently complicated regions of the MDV genome. 
Recently, we reported an immediate-early (IE) tran- 
script derived from the MDV IRL region (14). With cDNA 
cloning and sequencing, two cDNAs (O1 and C2) were 
identified. Both cDNAs are derived from spliced mRNAs 
spanning the BamHI-H and -12 fragments. C1 and C2 use 
the same splice accepters and 3' ends, but differ at their 
5' ends and utilize different splice donors. Combined 
with data from Peng et al. (23), we found that at least 
three distinct cDNAs, which utilize different splice donors 
but share a common accepter site, are transcribed 
across the BamHI-H and -12 fragments of MDV. Despite 
abundant ranscription as detected by Northern blot anal- 
ysis, only two small open reading frames (ORFs) were 
found within each cDNA (01 contains ORFla of 83 amino 
acids and ORF2 of 107 amino acids, while C2 cDNA may 
encode 76 amino acids for ORFlb and the same 107 
amino acids for ORF2 as in O1). To understand the func- 
tion of these spliced transcripts, particularly with regards 
to the potential importance of this region in viral oncoge- 
nicity, we focused on identification of a possible protein 
product encoded by these transcripts. Using rabbit anti- 
sera raised against fusion proteins glutathione S-trans- 
ferase (GST)-ORFla and GST-ORFlb, we have demon- 
strated that a 14-kDa polypeptide (p14), which is recog- 
nized by both antisera, is expressed in cells lytically 
infected with both oncogenic and attenuated MDV as 
well as in cells latently transformed by MDV. In this pa- 
per, we further characterized the properties of the gene 
product encoded by this immediate-early gene. 
Previously, we found that antisera raised against 
ORFla and ORF1 b detected polypeptides of similar size 
on Western blots (14). Since ORF1 a and ORF1 b only differ 
in their first exon sequences (39 bp or 13 amino acids 
for ORFla, 18 bp or 6 amino acids for ORFlb) (Fig. 1A), 
it was of interest o determine whether these two antisera 
can cross-react with both ORFla- and ORFlb-derived 
polypeptides and whether they detect the same polypep- 
tide. Cross-reaction of anti-ORFla and anti-ORFlb sera 
was examined by conducting competition immunoprecip- 
itation prior to Western blot analysis. Cell lysate from 
duck embryo fibroblast cells (DEF) infected with MDV 
strain GA were immunoprecipitated with normal rabbit 
serum or anti-ORFlb serum. Supernatants were sub- 
jected to Western blot analysis and examined by anti- 
ORFla serum as previously described (Fig. 1B, lanes 3 
and 4) (14). Cell lysates immunoprecipitated with anti- 
ORFla were used as a positive control for clearance 
(Fig. 1B, lane 5). Immunoprecipitation with normal rabbit 
serum has no effect on p14 detection by anti-ORFla se- 
rum (Fig. 1B, lane 3). However, p14 was significantly 
reduced in cell lysates which have been immuneprecipi- 
tated with anti-ORF1 b serum prior to Western blot analy- 
sis by anti-ORFla serum (Fig. 1 B, lane 4). Similar results 
were obtained in a complementary experiment where 
p14 detected by anti-ORFlb was almost completely 
blocked in cell lysates immunoprecipitated with anti- 
ORFla serum (Fig. 10, lane 4). Immunoprecipitation with 
normal rabbit serum had little or no effect on availability 
of p14 (Fig. 10, lane 3). Cell lysates immunoprecipitated 
with anti-ORF1 b were used as positive control for clear- 
ance (Fig. 10, lane 5). Similarly, "cross-absorption" exper- 
iments were conducted. Anti-ORFla serum was preab- 
sorbed with purified GST-ORF1 b fusion protein and anti- 
ORF1 b serum was preabsorbed with GST-ORFla fusion 
protein prior to use in Western blot detection of p14. 
GST-ORFlb fusion protein removed all specific binding 
activity from anti-ORFla serum. Similarly, GST-ORFla 
fusion protein removed all p14-specific binding activity 
from anti-ORFlb serum (data not shown). These results 
indicate that the unique amino acids encoded by each 
first exert in C1 arid 02 cDNA, if translated, do not com- 
prise strong epitopes. The 14-kDa polypeptides detected 
by anti-ORFla and anti-ORFlb sera are highly related 
and may represent the same polypeptide. Although we 
temporarily designate the proteins as a single polypep- 
tide, p14, It is possible that there are two distinct proteins 
differing in only a few amino acids. Subtle changes in 
amino acid sequence may result in secondary structure 
and protein function changes, thus providing a way for 
these differently spliced transcripts to execute distinct 
functions. Peptide mapping and/or amino acid sequence 
analysis will be required to fuFther clarify this question. 
p14 is a MDV serotype 1 specific antigen. Protein data 
base searches failed to identify any significant homology 
between p14 and any known protein sequence, sug- 
gesting that p14 represents a MDV specific antigen (14). 
Previous identification of p14 was limited to cells lytically 
infected with oncogenic serotype 1 MDV and their attenu- 
ated .derivatives (strains GA, Mdllp16, and Mdllp83) 
(14), we therefore extended our study to two other MDV 
serotypes. Serotype 2 represents naturally occurring, 
nononcogenic strains of MDV, while serotype 3 repre- 
sents nononcogenic HVT (27). Extensive use of serotype 
2 and serotype 3 as live virus vaccines to prevent MDV 
serotype 1-induced tumor formation indicates that anti- 
gens in these three serotypes share common epitopes 
(12, 17). Western blot analysis of DEF cells infected with 
MDV strain GA passage 7 (a representative of serotype 
1), MDV strain 281 MI/1 passage 16 (representative of 
serotype 2), and HVT passage 7 (representative of sere- 
type 3), along with uninfected DEF was performed using 
anti-ORFla (Fig. 2A) and anti-ORFlb (data not shown) 
sera. Anti-MDV gB Z45 (kindly provided by Dr. L. Velicer, 
Michigan State University), which can detect MDV gB 
antigen present in cells infected with all three serotypes 
of MDV, was used as a positive control (data not shown). 
Interestingly, p14 was only detected in lysates of cells 
infected with serotype 1 MDV (Fig. 2A, lane 2). No homo- 
log of MDV p14 was detected in cells infected with MDV 
serotypes 2 or 3 (Fig. 2A~ lanes 3 and 4, respectively). It 
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FIG. 1. Antigenic relatedness of ORFla and ORFlb. (A) Schematic representation of MDV genome structure with enlarged restiiction map of 
BamHI-H and Iz regions. A dark line represents the region from which C1 and 02 cDNAs, as well as other MDV transcripts (1, 2, 7, 23), are derived. 
Shaded boxes represent he 132-bp repeat region. Locations of C1 and 02 clDNAs are shown with approximate introns and open reading frames 
(black boxes). ORFla of O1 is 83 amino acids. ORFlb of C2 is 76 amino acids. ORF2 in both C1 and C2 is 107 amino acids. (B) Western blot 
analysis by anti-ORFla serum. Lane 1 is lysate from uninfected DEF cells, lane 2 is lysate from IDEF cells infected with MDV strain GA, lanes 3, 4, 
and 5 are MDV GA-infected DEF cell lysate which have been immunoprecipitated with normal rabbit serum, anti-ORFlb, and anti-ORFla sera, 
respectively, prior to electrophoresis and transfer. All lysates were resolved in 12.5% SIDS-PAGE gels and transferred to nitrocellulose membrane, 
followed by immune-detection using anti-ORFla serum. (C) Western blot analysis by anti-ORFlb serum. Lanes 1, 2, and 3 are the same as those 
described for A. Lanes 4 and 5 are MDV-infected IDEF cell lysates which have been immunoprecipitated with anti-ORFla and anti-ORFlb sera, 
respectively, prior to electrophoresis and transfer. 
is possible that p14 detected in attenuated Mdllp83, 
reported previously, is due to unattenuated virions pres- 
ent in a heterogenous virus population. We believe this 
to be highly unlikely in view of the following facts= (1) 
The Mdllp83 virus stock used in previous studies has 
been shown to be highly attenuated (Wilson, Schat, and 
0oussens, manuscript in preparation). (2) If oncogenic 
virions do remain in the Mdllp83 stock, they compose 
a very small proportion of total virions. If p14 expression 
is restricted to oncogenic virions, one would expect a 
considerably reduced level of p14 in cells infected with 
Mdllp83; however, the levels of p14 observed in West- 
ern blots of Mdl lp16 (oncogenic) and Mdl lp83 (attenu- 
ated) are very similar. (3) Analysis of a clonal Mdllp83 
derivative isolated by electroporation of CEF cells (30) 
revealed similar levels of p14 (data not shown). There- 
fore, p14 represents a protein specific to oncogenic and 
attenuated serotype 1 MDV. This finding is consistent 
with p14 coding sequences mapping within IRL regions 
of the MDV genome. IRL regions do not share extensive 
homology among the three MDV serotypes (3, 16). 
The 14-kDa polypeptide identified previously (14) is 
significantly larger than 9.6 and 10.3 kDa calculated from 
ORFla and ORFlb DNA sequences, respectively (14). 
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FiG. 2. Characterization ofp14. (A) Western blot analysis of p14 serotype specificity. Lane 1, lysate from uninfected DEF; lane 2, lysate from DEF 
infected with MDV strain GA (serotype 1); lane 3, lysate from DEF infected with MDV strain 281MI/1 (serotype 2); lane 4, lysate from DEF infected 
with HVT (serotype 3). Proteins were detected by anti-ORFla serum. (B) Immunoprecipitation f p14 as phosphoprotein (pp14). Uninfected DEF 
cells and DEF cells infected with MDV strain GA were preincubated inphosphate-free Dulbecco's modified Eagle's medium (Gibco-BRL, Gaithersburg, 
MD) for 1 hr. [32P]Orthophosphate (500/~Ci) was added to each 60-mm plate and cells were continuously abeled for 4 hr prior to harvesting. Cell 
lysates were immunoprecipitated with anti-QRFla serum as described (12). The immunoprecipitates were analyzed by 12.5% SDS-PAGE. Lane 1, 
lysate from uninfected DEF cells; lane 2, lysate from DEF infected with MDV strain GA; lane 3, same as lane 2, except calf intestinal phosphatase 
(OtP) added following immunoprecipitation. (C) Western blot analysis of subcellular f actions. Lane 1, whole cell [ysate of uninfected DEF; lane 2, 
whole cell lysate of DEF infected with MDV strain GA; lane 3, cytoplasmic fraction of MDV GA-infected DEF cells; lane 4, nuclear fraction of MDV 
GA-infected DEF cells. 
ORFla has two potential casein kinase consensus phos- 
phorylation sequences (amino acids 5 and 66) and four 
potential histone kinase consensus phosphorylation 
sites (amino acids 9, 42, 49, and 63). ORFlb has one 
casein kinase phosphorylation consensus sequence 
(amino acid 59) and three potential histone kinase phos- 
phorylation sequences (amino acid 35, 42, and 66) (14). 
Extensive phosphorylation or other post-translation mod- 
ification can change protein secondary structure and sur- 
face charges, resulting in slow apparent mobility of pro- 
teins (10). To determine whether the 14-kDa polypeptide 
identified in this study is phosphorylated, we immunopre- 
cipitated lysates from 32p-labeled uninfected DEF and 
ME)V strain GA-infected DEF cells with anti-ORFla (Fig. 
2B, lanes 1 and 2) serum as described (12). MDV-infected 
cell immunoprecipitates were divided into two parts. 
One part was subjected to treatment with calf intestinal 
phosphatase (OIP) for 1 hr at 37 ° (Fig. 2B, lane 3) (22). 
All immunoprecipitates were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (Fig. 2B). Results of SDS-PAGE analysis 
demonstrate that p14 is phosphorylated (Fig. 2B, lane 2). 
Significant reduction in intensity of p14 bands in CIP- 
treated sample indicates sensitivity of phosphoprotein 
p14 to phosphatase (Fig. 2B, lane 3). This result supports 
our previous hypothesis that phosphorylation of p14 may 
be one factor contributing to the discrepancy between 
calculated and apparent sizes of p14, However, when 
cell lysates from ME)V-infected cells were treated with 
CIP and Western blot analysis was conducted, only a 
slight shift (1-2 kDa) was observed relative to untreated 
p14 (data not shown). Thus, phosphorylation is not the 
only factor contributing to the apparent size discrepancy. 
Computer analysis also indicated potential N-glycosyla- 
tion sites exist within ORFla (three sites) and ORFlb 
(two sites). However, treatment of infected cells with tuni- 
camycin prior to Western blot analysis had little or no 
effect on the apparent size of p14 (data not shown). Our 
results clearly demonstrate that p14 is a phosphoprotein. 
Furthermore, neither phosphorylation nor glycosylation 
is completely responsible for the discrepancy between 
calculated and apparent size of p14. Protein phosphory- 
lation is a well known method for mediating activity of 
proteins involved in regulation of gene expression and 
other regulatory functions (review, 15). Since p14 is de- 
rived from an IE gene and many herpesvirus IE genes 
encode phosphorylated virus transcription factors, phos- 
phorylation of p14 was not entirely unexpected. We pro- 
pose that this MDV-specific polypeptide be designated 
pp14. 
pp14 is predominately located in the cytoplasm of MDV- 
infected cells. If pp14 functions primarily to regulate viral 
gene expression as do most other herpesvirus IE gene 
products, one might expect a significant portion of pp14 to 
be localized in the nucleus of infected cells. To determine if 
pp14 is a nuclear phosphoprotein, we prepared subcellular 
fractions from MDV strain GA-infected DEF cells as de- 
scribed (25) and assayed fractions for pp14 by immunoblot- 
ting (Fig. 2C). Surprisingly, pp14 was detected exclusively 
in cytoplasmic fractions (Fig. 20, lane 3). An anti-chicken 
hMG14/17 antibody (kindly provided by Dr. M. Bustin, NIH), 
which detects a predominately nuclear protein hMG14/17, 
was used as a positive control to confirm the presence of 
nuclear proteins (data not shown). 
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FiG. 3. Localization of pp14 by indirect immunofluorescence. Primary DEF cells and DEF ceils infected with MDV strain GA, prepared as described 
by Glaubiger et aL (12), were grown on glass coverslips. Cells were fixed by acetone/methanol (1/1) for 3 min, washed extensively with PBS, and 
preincubated with 3% bovine serum albumin for 1 hr at room temperature. Anti-ORFla serum or preimmunoserum (data not shown) was added to 
the cells in a 1~20 dilution and incubated for 1 h at room temperature. Goat anti-rabbit IgG conjugated with phycoerythrin (Sigma, St. Louis, MO) 
was used as secondary antibody in a dilution of 1,20 in PBS. Slow-Fade (Molecular Probes, Eugene, OR) was added prior to mounting to glass 
slides to prevent quenching of fluorescence. Confocal fluorescence images w re acquired using the Meridian INSIGHT-PLUS laser scanning 
confocal microscope (Meridian Instrument, Okemos, MI). Fluorescent labels were excited using the 488mm argon laser line. Emissions were 
acquired using 580/30-nm band pass filter with 100x Olympus Splan APo (1.4 NA) objective and 2.5X photo eyepiece and detected through 
integration on a cooled-CCD camera. (A) Uninfected DEF cells. (B) DEF infected with MDV strain GA. 
To confirm the intracellular localization of pp14, we 
extended our analysis by employing indirect immunofluo- 
rescence. DEF cells (uninfected and infected with MDV 
strain GA) were grown on coverslips, fixed by acetone/ 
methanol, washed, and stained as described (13). Anti- 
ORFla serum was added to cells at a 1=20 dilution and 
incubated for 1 hr at room temperature. Goat anti-rabbit 
IgG conjugated with phycoerythrin (Sigma, St. Louis, MO) 
was used as secondary antibody in a dilution of 1=20. 
0overslips were washed with PBS and mounted on glass 
slides with Slow-Fade (Molecular Probes, Eugene, OR) 
to prevent quenching of fluorescence. Confocal fluores- 
cence images were acquired using the Meridian IN- 
SIGHT-PLUS laser scanning confocal microscope (Me- 
ridian Instruments, Inc., Okemos, MI). Fluorescent labels 
were excited using a 488-nm argon laser line. Emissions 
were acquired using 580/30-nm band pass filter and de- 
tected through integration on a cooled-CCD camera. 
Specific staining of pp14 was localized to the cytoplasm 
of MDV-infected cells, primarily in areas near the nucleus 
(Fig. 3). To confirm the immune signals detected by anti- 
0RFla serum were truly in MDV-infected cells, we chose 
MDV gB as a positive control and conducted double- 
stained immunofluorescence. Monoclonal anti-MDV/gB 
antibody (generously provided by Dr. L. Lee, USDA- 
ADOL) was detected with a secondary goat anti-mouse 
IgG antibody conjugated with fluorescein-5'-isothiocya- 
nate (FITC) (Coppel, Durham, NC) (1=20 dilution) using 
530/30-nm band pass filter. All cells staining with anti- 
ORFla or anti-ORF1 b (Phycoerythrin) also displayed anti- 
gB binding activity (FITC) (data not shown). Expression 
of pp14 in MDV-transformed tumor cell lines (14) and as 
a MDV serotype 1-specific antigen suggests that this 
protein may be associated with MDV tumorigenicity. Al- 
though pp14 was detected in both oncogenic and attenu- 
ated MDV serotype 1 strains (14), subtle changes or mod- 
ifications of protein content in attenuated strains may 
dramatically affect protein function. It is of considerable 
interest that pp14 is encoded by spliced transcripts from 
which the 132-bp expansion region is removed. Similar 
to immediate-early gene products of HSV-1 (26), pp14 is 
a phosphorylated protein. However, Western blot analy- 
sis of subcellular fractions and immunofluorescence de- 
tection both revealed that pp14 is predominately a cyto- 
plasmic protein. It is, however, possible that pp14 is 
transported to the nucleus in limited amounts. Nuclear 
transport of transcription factors is a commonly used 
mechanism of regulation in eukaryotic cells. Lack of a 
consensus nuclear transport signal in pp14 suggests that 
another factor would have to be involved in transport to 
the nucleus. Properties of pp14 presented in this report 
provide clues for further investigation of this serotype 1 
MDV-specific IE gene product. Functional and biochemi- 
cal analysis of this unique protein are in progress and 
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will be an important issue for understanding a potential 
role of pp14 in MDV-induced tumorigenicity. 
ACKNOWLEDG M ENTS 
This project is supported by the Michigan Agriculture Experiment 
Station, Research Excellence Fund, State of Michigan, and Grants g0- 
34116-5329 and 92-8420-7430 awarded to P. M. Coussens under the 
Competitive Research Grants Program administered by the U.S. Depart- 
ment of Agriculture. We thank Drs. M. Bustin, L. Lee, and L. Velicer for 
kindly providing antibodies used in these studies. We also thank R. 
Southwick for excellent technical assistance and assistance with 
graphic preparation. 
REFERENCES 
1. BRADLEY, G., HAYASHI, M., LANCZ, G., TANAKA, A., and NONOYAMA, M., 
J. Virol. 63, 2534-2542 (1989). 
2. BRADLEY, G., LANCZ, G., TANAKA, A., and NONOYAMA, M., J. ViroL 63, 
4129-4136 (1989). 
3. BUOKMASTER, A. E., ScoTt, S. D., SANDERSON, M. J., BOURSNELL, 
M. E. G., Ross, N. L. J., and BINNS, M. M., ./. Gen. Virol. 69, 2033- 
2042 (1988). 
4. CALNEK, B. W., Grit. Rev. MicrobioL 12, 293-320 (1985). 
5. CEBRIAN, J., KASCHKA-D[ERICH, C., BERTHELOT, N., and SCHELDRICK, P., 
Prec. Natl. Acad. ScL USA 79, 555-558 (1982). 
6. OHEN, X., SONDERMEIJER, P. J., and VELICER, L. F., Z ViroL 66, 85-94 
(1992). 
7. CHEN, X., and VELIOER, L. F., ./. Virol. 65, 2445-2451 (1991). 
8. CHURCHILL, A. E., and BIGGS, P. M., Nature 215, 528-530 (1967). 
9. Cut, Z., LEE, L. F., LIU, J.-L., and KUNG, H.-J., J. ViroL 65, 6509-6515 
(1991). 
10. DECAPRIO, J. A., LUDLOW, J. W., LYNCH, D., FURUKAWA, Y., GRIFFIN, J., 
PIWNICA-WORMS, H., HUANG, C.-M., and LIVINGSTON, D. M., Ceil 
58, 1085-1095 (1984). 
11. FUKUOHI, K., SUDO, M., LEE, Y-S., TANAKA, A., and NONOYAMA, M., J. 
Virol. 51, 102-109 (1984). 
12. GLAUBIGER, O.i NAZERIAN, K., and VELICER, h F., J. ViroL 45, 1228- 
1234 (1983), 
13. HARLOW, E., and LANE, D., "Antibodies, a Laboratory Manual." pp. 
359-420. Cold Spring Harbor Laboratory, Cold Spring Harbor, 
NY, 1988. 
14. HONG, Y., and COUSSENSS, P. M., ./. ViroL 68, 3593-3603 (1994). 
15. HUNTER, T., and KARIN, M., Cell 70, 375-387 (1992). 
16. [GARASHI, m., TAKAHASHI, M., DONQVAN, J., JESSIP, J., SMITH, M., HIRAI, 
K., TANAKA, A., and NONOYAMA, M., Virology 157, 351-358 (1992). 
1Z. ISFORT, R. J., SITHOLE, I., KUNG, H.-J., and VELICER, L. F., J. Virol. 59, 
411-419 .(1986). 
18. JONES, D., LEE, L., LIU1 J.-L., KUNG, H. J., and TILLOTSON, J. K., Proc. 
Natl. Acad. SeL USA 89, 4042-4046 (1992). 
19. KAWAMURA, M., HAYASHI, M,, FURUlOHI, T., NONOYAMA, M., ISOGAI, E., 
and NAMIOKA, S.,./. Gen. ViroL 72, 1105-1111 (1991). 
20. MAOTANI, K., KANAMORI, A., IKUTA, K., UEDA, S., KATO, S., and HIRAI, 
K., J. ViroL 58, 657-660 (1986). 
21. MARAY, T., MALKINSON, M., and BECKER, Y., Virus Genes 2, 49-68 
(1988). 
22. MORRISON, D. K., KAPLAN, D. R., ESOOBEDO, J. A., RAPP, U. R., ROBERTS, 
T. M., and WILLIAMS, L. m., Ceil 58, 649-657 (1989). 
23. PENG, F., BRADLEY, G., TANAKA, A., LANCZ, and NONOYAMA, M.,J. ViroL 
66, 7389-7396 (1992). 
24. PENG, F., DONOVAN, J., SPECTER, S., TANAKA, A., and NONOYAMA, M., 
Intern. J. OncoL 3, 587-591 (1993). 
25. RAMSAY, G., STANTON, L., SCHWAB, M., and BISHOP, J. M., MoL Cell. 
BioL 6, 4450-4457 (1986). 
26. ROIZMAN, B., and SEARS, A. E., In "Fundamental Virology" (B. N. 
Fields and D. M. Knip, Eds.), 2rid ed. pp. 849-896. Raven Press, 
New York, 1990. 
27. SCHAT, K. A., fn "Marek's Disease, Scientific Basis and Methods of 
Control" (L. N. Payne, Ed.), pp. 77-112. N ijhoff, Boston, MA 1985. 
28. SCHAT, K. A., BUCKMASTER, A., and Ross, L. J. N., Int. J. Cancer 44, 
101-109 (1989). 
29. S{LVA, R. F., and WIIq-ER, R. L,J. ViroL 54, 690-696 (1985). 
30. WILSON, M. R., and COUSSENS, P. M., Virology 185, 673-680 (1991). 
